Skip to main content
  1. Home
  2. Emerging Tech
  3. News

The FTC wants to know if Juul used influencers to target e-cigarettes at minors

Add as a preferred source on Google

The Federal Trade Commission (FTC) has started an investigation into marketing practices used by popular e-cigarette company Juul, including its use of influencers on social media, but the company told Digital Trends that it spent very little on influencer marketing and never targeted teens.

The Wall Street Journal reports that FTC investigators are looking into whether or not Juul used deceptive marketing practices to target their products to minors. Investigators are also interested in Juul’s hiring of influencers to promote its e-cigarette products and whether influencers were used to attract minors.

Recommended Videos

“Without commenting on any specific investigation, our paid influencer program, which was never formalized, was a small, short-lived pilot that ended in 2018,” a Juul spokesperson told Digital Trends. “We worked with fewer than 10 adults on JUUL-related content, and they were all smokers or former smokers over the age of 30.

The spokesperson added that it spent “less than $10,000” on influencers.

The company said that they have deleted all of its social media and “request that social media platforms delete inappropriate third party posts and listings.”

Juul said that they are cooperating with the investigation, but denied that they market to youth.

“Our earliest marketing campaign in 2015 was intended for adults in the 25-34 year-old demographic and lasted for six months. If one views the sales and revenue data, there is no evidence that it drove use, youth or otherwise. Nonetheless, we regret that the campaign was executed in a way that was perceived as appealing to minors,” the Juul spokesperson said.

The company announced new “aggressive steps” that include implementing “the strictest age-verification point-of-sale standards ever imposed for an age-restricted product at retail.” Juul also announced a “Track & Trace” program that traces confiscated Juul devices.

“We have no higher priority than to prevent youth usage of our products.  Our product is intended for current adult smokers and our marketing specifically is designed to help achieve that goal,” Juul told Digital Trends.

According to reports, the FTC has been working for the past year to start an investigation into the e-cigarette company. Last September, the FTC requested marketing information from Juul.

The FTC isn’t the only one who has been interested in the company’s practices; last October, the Food and Drug Administration (FDA) conducted a surprise inspection of Juul’s headquarters, according to CNBC.

“We’re going to be taking a series of escalating actions under our new Youth Tobacco Prevention Plan, beginning with our actions last week targeting JUUL products, and continuing with today’s effort with our partners at the FTC. We appreciate the FTC in joining us in these actions,” FDA Commissioner Scott Gottlieb, M.D. said in an FTC press release from last year.

On Thursday, Bloomberg reported that an FDA investigation into whether vaping causes seizures was kicked off by reports of seizures hitting people who use Juul devices.

The Centers for Disease Control and Prevention announced earlier this month that it had found 149 cases of serious lung disease linked to e-cigarette use and was looking into the matter further.

Juul advertises its vaping products as being a safer and healthier substitution to traditional cigarette smoking. However, studies consistently show e-cigarette smokers are less likely to quit than regular smokers who have never used these kinds of devices.

In June, San Francisco, where Juul is headquartered, became the first city in the U.S. to ban the sales of e-cigarettes.

Digital Trends also reached out to the FTC for more details on the investigation, but we haven’t received a response.

Allison Matyus
Former Digital Trends Contributor
Allison Matyus is a general news reporter at Digital Trends. She covers any and all tech news, including issues around social…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more